The use of ribociclib in real clinical practice: results of a single-center observational retrospective study-Reference-Cited by-同舟云学术

The use of ribociclib in real clinical practice: results of a single-center observational retrospective study

Published:2024-01-17 Issue:22 Volume: Page:130-138
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Sultanbaev A. V.¹^ORCID,Kolyadina I. V.²^ORCID,Musin Sh. I.¹^ORCID,Nasretdinov A. F.¹^ORCID,Sultanbaeva N. I.¹^ORCID,Menshikov K. V.³^ORCID,Menshikova I. A.⁴^ORCID,Askarov V. E.¹^ORCID,Rakhimov R. R.¹^ORCID,Lipatov D. O.³^ORCID,Lipatov O. N.³^ORCID,Sultanbaev M. V.⁴^ORCID,Zabelin V. M.⁵^ORCID,Izmailov A. A.⁶^ORCID,Ayupov R. T.¹^ORCID,Izmailov A. A.¹^ORCID

Affiliation:

1. Republican Clinical Oncology Dispensary

2. Russian Medical Academy of Continuous Professional Education; Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology

3. Republican Clinical Oncology Dispensary; Bashkir State Medical University

4. Bashkir State Medical University

5. Pirogov Russian National Research Medical University

6. Bashkir State Medical University; Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Center

Abstract

Introduction. The standard initial treatment for patients with hormone receptor positive, HER2 negative, metastatic breast cancer (HR+/HER2– mBC) involves the use of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy. The combination therapy has proven effectiveness in numerous Phase II and III randomized controlled trials (RCTs). Nonetheless, RCTs may not fully represent real-world clinical situations due to their stringent inclusion criteria, resulting in a specific patient population.Aim. Analyze of ribociclib using for treating patients with HR+/HER2– advanced breast cancer (mBC) at the Republican Clinical Oncology Dispensary.Materials and methods. Patients diagnosed with HR+/HER2– mBC who were treated in clinical routine with ribociclib in combination with different endocrine agents between 2016 and 2020 were identified and enrolled in this retrospective study. Clinicopathological characteristics and clinical outcomes were recorded with particular emphasis on ribociclib therapy course (progression-free survival (PFS), toxicity, dose reduction).Results. Data from n = 101 patients were evaluated. The mean patient age was 61 years. The study included 67 (66.3%) patients with progression after radical treatment and 34 (33.7%) patients with primary disseminated breast cancer. Dose reduction due to adverse events was performed in n = 14 cases (13.9%). Presence of prior therapy lines and lower ECOG status were associated with shorter PFS, whereas estrogen positivity and the choice of fulvestrant over aromatase inhibitor were positively associated with PFS. Metastatic pattern, progesterone positivity and dose reduction due to toxicity did not significantly impact on PFS.Conclusion. Our real-world data analysis on ribociclib treatment in Russian regional hospital supports data from RCTs regarding both treatment efficacy and safety of CDK4/6i for treatment of patients with HR+/HER2– mBC. Currently, by expanding our experience with CDK4/6 inhibitors in different groups of patients with mBC, we will be able to provide patients with optimal treatment options.

Publisher

Remedium, Ltd.

Reference30 articles.

1. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2021 г. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022. 239 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf.

2. Parise CA, Caggiano V. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. J Cancer Epidemiol. 2014:469251. https://doi.org/10.1155/2014/469251.

3. Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol. 2015;12(9):541–552. https://doi.org/10.1038/nrclinonc.2015.99.

4. Flaum LE, Gradishar WJ. Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer. In: Gradishar W (ed.). Optimizing Breast Cancer Management. Cancer Treatment and Research. Vol. 173. Springer, Cham; 2018, pp. 141–154. https://doi.org/10.1007/978-3-319-70197-4_9.

5. Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Künzer H et al. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. J Natl Cancer Inst. 2004;96(3):210–218. https://doi.org/10.1093/jnci/djh022.